GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Net Interest Income

CanSino Biologics (HKSE:06185) Net Interest Income : HK$21.2 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. CanSino Biologics's net interest income for the three months ended in Dec. 2024 was HK$0.0 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2024 was HK$21.2 Mil.

CanSino Biologics Net Interest Income Historical Data

The historical data trend for CanSino Biologics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Net Interest Income Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only 37.44 72.19 26.91 39.06 3.97

CanSino Biologics Quarterly Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.47 7.08 25.39 -18.74 -

CanSino Biologics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$21.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Net Interest Income Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Net Interest Income
Comparable Companies
HKSE:01558 HKSE:00570 HKSE:02005 HKSE:01681 HKSE:02186 HKSE:03613 HKSE:01349 HKSE:00460 HKSE:02877 HKSE:02561 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
CASBF:USA CJH:Germany 688185:China
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
Website
https://www.cansinotech.com
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Executives
Yu Xuefeng 2501 Other
Chao Shou Bai 2202 Interest of your spouse
Mao Helen Huihua 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Zhu Tao
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics Headlines

No Headlines